Tarsus Pharmaceuticals (TARS) Earnings Date, Estimates & Call Transcripts → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free TARS Stock Alerts $36.62 +2.58 (+7.58%) (As of 03:34 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 8EstimatedActual EPS (Feb. 27) -$1.31 Beat By $0.06 Consensus EPS (Feb. 27) -$1.37 Read Call TranscriptListen to Call Get Tarsus Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for TARS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTARS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TARS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Tarsus Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($1.28)($1.16)($1.22)Q2 20242($1.32)($1.08)($1.20)Q3 20242($1.43)($1.02)($1.23)Q4 20242($1.33)($0.97)($1.15)FY 20248($5.36)($4.23)($4.80)Q1 20251($1.36)($1.36)($1.36)Q2 20251($1.04)($1.04)($1.04)Q3 20251($0.84)($0.84)($0.84)Q4 20251($0.46)($0.46)($0.46)FY 20254($3.70)($3.70)($3.70)TARS Earnings Date and InformationTarsus Pharmaceuticals last released its quarterly earnings data on February 27th, 2024. The reported ($1.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $4.63 million. Tarsus Pharmaceuticals has generated ($4.64) earnings per share over the last year (($4.64) diluted earnings per share). Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.25) to ($2.16) per share. Tarsus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off prior year's report dates.Read More Tarsus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/8/2024Estimated)------- 2/27/2024Q4 2023($1.37)($1.31)+$0.06($1.31)$4.63 million$13.08 million 11/9/2023Q3 2023($1.40)($1.28)+$0.12($1.28)$0.72 million$1.87 million8/10/2023Q2 2023($1.08)($1.17)($0.09)($1.17)--5/9/2023Q1 2023($0.95)($0.88)+$0.07($0.88)$3.33 million$2.50 million3/13/2023Q4 2022($0.97)($0.49)+$0.48($0.49)$11.67 million$10.00 million11/9/2022Q3 2022($0.98)($0.84)+$0.14($0.84)-- Get the Latest News and Ratings for TARS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022($0.65)($0.24)+$0.41($0.24)$16.67 million$15.28 million5/10/2022Q1 2022($0.87)($0.98)($0.11)($0.98)$5.50 million$0.54 million3/14/2022Q4 2021($0.77)($0.72)+$0.05($0.72)$7.11 million$0.34 million11/9/2021Q3 2021($0.42)($0.76)($0.34)($0.76)$1.00 million$1.24 million8/4/2021Q2 2021($0.52)$0.29+$0.81$0.29$10.00 million$22.02 million5/11/2021Q1 2021($0.64)$0.47+$1.11$0.47-$33.43 million Tarsus Pharmaceuticals Earnings - Frequently Asked Questions When is Tarsus Pharmaceuticals's earnings date? Tarsus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates. Learn more on TARS's earnings history. Did Tarsus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Tarsus Pharmaceuticals (NASDAQ:TARS) reported ($1.31) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.37) by $0.06. Learn more on analysts' earnings estimate vs. TARS's actual earnings. How can I listen to Tarsus Pharmaceuticals's earnings conference call? The conference call for Tarsus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Tarsus Pharmaceuticals's conference call transcript? The conference call transcript for Tarsus Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Tarsus Pharmaceuticals generate each year? Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded annual revenue of $17.45 million. How much profit does Tarsus Pharmaceuticals generate each year? Tarsus Pharmaceuticals (NASDAQ:TARS) has a recorded net income of -$135.89 million. TARS has generated -$4.64 earnings per share over the last four quarters. What is Tarsus Pharmaceuticals's EPS forecast for next year? Tarsus Pharmaceuticals's earnings are expected to grow from ($4.25) per share to ($2.16) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Scholar Rock Earnings Date Cullinan Oncology Earnings Date Autolus Therapeutics Earnings Date 4D Molecular Therapeutics Earnings Date Relay Therapeutics Earnings Date BioCryst Pharmaceuticals Earnings Date Immatics Earnings Date Mesoblast Earnings Date REGENXBIO Earnings Date CARGO Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:TARS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.